<DOC>
	<DOCNO>NCT01621672</DOCNO>
	<brief_summary>The purpose study determine phase II trial , whether maintenance therapy Revlimid extend duration progression-free survival duration complete near complete response compare therapy beyond TT3 protocol-prescribed 3 year maintenance 1 year VTD plus 2 year TD , 3 year VTD ( 2003-33 ) VRD ( 2006-66 ) .</brief_summary>
	<brief_title>UARK 2009-09 Myeloma Cure Project : Prospective Trial Indefinite Revlimid Maintenance Versus Observation Currently Event-Free Patients With Multiple Myeloma</brief_title>
	<detailed_description>Determine associate toxicity qualitative quantitative term use NCI CTCAE ( NCI common terminology adverse event )</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Male female participant races/ethnicities multiple myeloma previously enrol UARK 200333 200666 . Participant complete 3 year maintenance therapy one three study drug VTD VRD disease status remain event free ( include patient prematurely discontinue maintenance therapy long 3 year elapse since begin maintenance ) . All patient must age 18 year age great time signing informed consent form . Participant adequate hematopoietic reserve , define platelet &gt; 50,000/μL ( participant bone marrow hypoplasia , remain peripheral blood progenitor cell infuse boost hematopoietic reserve prior enrollment ) . Participant adequate renal function define serum creatinine &lt; 3 mg/dL prior enrol study Total bilirubin ≤ 1.5 mg/dL prior enrol study AST ( SGOT ) ALT ( SGPT ) ≤ 2 x ULN prior enrol study Patient must sign IRBapproved informed consent understand investigational nature study . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® Pregnant nurse woman may participate . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prescribe Revlimid® ( lenalidomide ; prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take Revlimid® ( lenalidomide ) . FCBP must also agree ongoing pregnancy test . Lactating female must agree breastfeed . Men must agree use latex condom sexual contact FCBP even successful vasectomy . See Appendix : Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods † A female childbearing potential sexually mature woman : undergone hysterectomy bilateral oophorectomy naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . Any condition PI believe , laboratory abnormality , psychiatric illness would prevent subject enrol research study . Pregnant breast feeding female . ( Lactating female must agree breast feed take Revlimid® ) Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 28 day baseline . Known hypersensitivity thalidomide . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Concurrent use anticancer agent treatment . Known positive HIV infectious hepatitis , type B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Revlimid</keyword>
	<keyword>progression free</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>